MARKET

NVO

NVO

Novo Nordisk
NYSE

Real-time Quotes | Nasdaq Last Sale

67.54
+1.40
+2.12%
After Hours: 67.54 0 0.00% 13:01 11/27 EST
OPEN
66.54
PREV CLOSE
66.14
HIGH
67.65
LOW
66.51
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
73.81
52 WEEK LOW
49.24
MARKET CAP
119.18B
P/E (TTM)
24.17
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Novo Nordisk (NVO) a Suitable Stock for Value Investors?
Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Zacks · 4d ago
Novo Nordisk And Lego Board Member Joins Data-Focused Wellness Company Bellabeat
Benzinga · 6d ago
20 Largest European Companies By Market Cap in 2020
In this article we are going to list the 20 largest European companies by market cap in 2020. Click to skip ahead and jump to the 5 largest European companies by market cap in 2020. We are going to focus on what is probably the most developed continent in the world, and is the model […]
Insider Monkey · 11/20 13:42
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
Zacks · 11/18 16:24
Novo Nordisk Reports Headline Results From SUSTAIN FORTE Trial For Type-2 Diabetes Treatment
Novo Nordisk today announced headline results from the SUSTAIN FORTE trial, a phase 3b 40-week, efficacy and safety trial with once-weekly semaglutide 2.0 mg vs once-weekly semaglutide 1.0 mg as add-on to metformin
Benzinga · 11/17 14:29
Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial
Bagsværd, Denmark, 17 November 2020 - Novo Nordisk today announced headline results from the SUSTAIN FORTE trial, a phase 3b 40-week, efficacy and safety trial with once-weekly semaglutide 2.0 mg vs once-weekly semaglutide 1.0 mg as add-on to metformin and/or sulfonylureas in 961 people with type 2 diabetes in need for treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 40 with semaglutide 2.0 mg compared to semaglutide 1.0 mg. When evaluating the effects of treatment taken as intended1 and from a high mean baseline HbA1c of 8.9%, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c of 2.2% compared with a reduction of 1.9% with semaglutide 1.0 mg at week 40. The American Diabetes Association (ADA) treatment target of HbA1c below 7.0% was achieved by 68% of people treated with semaglutide 2.0 mg vs 58% on semaglutide 1.0 mg.From a mean baseline body weight of 99.3 kg, people treated with semaglutide 2.0 mg experienced a statistically significant1 and superior weight loss of 6.9 kg compared with 6.0 kg with semaglutide 1.0 mg.When applying the treatment policy estimand2, people treated with semaglutide 2.0 mg experienced a reduction in HbA1c of 2.1% compared to 1.9% for people treated with 1.0 mg dose at week 40. People treated with semaglutide 2.0 mg experienced a statistically non-significant weight loss of 6.4 kg compared with 5.6 kg with semaglutide 1.0 mg. Trial product estimand[1]Treatment policy estimand2 Once-weekly semaglutide2.0 mg1.0 mg2.0 mg1.0 mg HbA1c reduction2.2%*1.9%2.1%*1.9% Body weight reduction6.9 kg*6.0 kg6.4 kg5.6 kg *Statistically significant vs once-weekly semaglutide 1.0 mgIn the trial, both doses of semaglutide appeared safe and well-tolerated. The most common adverse events were gastrointestinal, the vast majority were mild to moderate and diminished over time and were consistent with the GLP-1 receptor agonist class. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg with nausea rates around 15% for both doses. The treatment discontinuation rates due to adverse events were similar and below 5% for both doses of semaglutide.“We are very pleased with the results from the SUSTAIN FORTE trial with the large HbA1c reduction from a high baseline as well as the safety and tolerability profile, which establish a attractive benefit-risk ratio for treatment of type 2 diabetes with semaglutide” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “Semaglutide 1.0 mg has across the SUSTAIN programme demonstrated that up to 80% of patients achieved HbA1c levels below 7%. This study demonstrates that patients in poor glycaemic control increase the likelihood of achieving their HbA1c target when treated with semaglutide 2.0 mg.”About the SUSTAIN clinical programme The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 11,000 adults with type 2 diabetes in total. Semaglutide 1.0 mg is approved under the brand name Ozempic® indicated for type 2 diabetes.About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.Further informationMedia:   Mette Kruse Danielsen+45 3079 8883mkd@novonordisk.com Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com     Investors:   Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com Mark Joseph Root+45 3079 4211mjhr@novonordisk.com Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement No 71 / 2020* * * 1 Based on the trial product estimand: treatment effect if all people adhered to treatment and did not initiate other type 2 diabetes therapies2 Based on the treatment policy estimand: treatment effect regardless of treatment adherence or initiation of other type 2 diabetes therapies Attachment * PR201117_SUSTAIN_FORTE
GlobeNewswire · 11/17 14:24
Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
Zacks · 11/16 18:31
Aeterna Zentaris Amends License Agreement With Novo Nordisk For Commercialization And Development Of Macimorelin; Co. To Receive €5M Upfront Payment
- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million   - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02
Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million   - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 · 11/16 13:23
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVO. Analyze the recent business situations of Novo Nordisk through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVO stock price target is 74.60 with a high estimate of 75.76 and a low estimate of 73.44.
EPS
Institutional Holdings
Institutions: 875
Institutional Holdings: 148.99M
% Owned: 8.44%
Shares Outstanding: 1.76B
TypeInstitutionsShares
Increased
192
2.74M
New
91
-998.66K
Decreased
232
5.43M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.12%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Helge Lund
President/Chief Executive Officer
Lars Fruergaard Joergensen
Vice Chairman/Director
Jeppe Christiansen
Chief Financial Officer/Executive Vice President/Primary Contact
Karsten Munk Knudsen
Chief Operating Officer/Executive Vice President
Maziar Doustdar
Executive Vice President/Chief Scientific Officer
Mads Krogsgaard Thomsen
Executive Vice President/Director of Human Resources
Monique Carter
Executive Vice President
Ludovic Helfgott
Executive Vice President
Doug Langa
Executive Vice President
Camilla Sylvest
Executive Vice President
Henrik Wulff
Director
Mette Boejer Jensen
Director
Kasim Kutay
Director
Anne Kverneland
Director
Thomas Rantzau
Director
Stig Stroebaek
Independent Director
Brian Daniels
Independent Director
Laurence Debroux
Independent Director
Andreas Fibig
Independent Director
Sylvie Gregoire
Independent Director
Liz Hewitt
Independent Director
Martin Mackay
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
08/06/2020
Dividend USD 0.3679776
08/14/2020
02/06/2020
Dividend USD 0.5613016
03/27/2020
08/09/2019
Dividend USD 0.31809
08/16/2019
03/26/2019
Dividend USD 0.557215
03/22/2019
08/21/2018
Dividend USD 0.327
08/17/2018
--
Dividend USD 0.578
03/23/2018
08/10/2017
Dividend USD 0.336
08/17/2017
03/28/2017
Dividend USD 0.479
03/23/2017
08/16/2016
Dividend USD 0.331
08/11/2016
03/24/2016
Dividend USD 0.699
03/18/2016
03/25/2015
Dividend USD 0.533
03/19/2015
03/27/2014
Dividend USD 0.606
03/21/2014
03/26/2013
Dividend USD 0.453
03/21/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Novo Nordisk A/S (ADR) stock information, including NYSE:NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.